目的 通過(guò)對(duì)用丹參多酚酸聯(lián)合依達(dá)拉奉治療急性腦梗死的療效進(jìn)行分析，同時(shí)觀察治療對(duì)血液流變學(xué)的影響，從而判斷兩種藥物聯(lián)合治療對(duì)于治療急性腦梗死的臨床價(jià)值。方法 將2016年1月—2018年12月在安陽(yáng)市第六人民醫(yī)院院神經(jīng)內(nèi)科接受診治的80例腦梗死患者使用隨機(jī)數(shù)表法對(duì)進(jìn)行分組，對(duì)照組、治療組各40例。對(duì)照組患者在常規(guī)治療基礎(chǔ)上使用依達(dá)拉奉注射液，治療組在對(duì)照組治療基礎(chǔ)上加用注射用丹參多酚酸0.13 g溶于0.9%氯化鈉注射液250 mL中靜脈滴注，1次/d。兩組經(jīng)過(guò)14 d的治療后，對(duì)比患者的治療效果、對(duì)治療前后血液流變學(xué)相關(guān)指標(biāo)的影響以及NIHSS評(píng)分改善狀況。結(jié)果 治療前兩組的NIHSS評(píng)分比較無(wú)統(tǒng)計(jì)學(xué)差異；治療后，兩組NIHSS評(píng)分均降低，且治療組的低于對(duì)照組，兩組比較差異具有顯著性（P<0.05）。治療后，對(duì)照組的總有效率為52.5%，治療組的總有效率為85.0%，且治療組的總有效率高于對(duì)照組，兩組比較差異具有顯著性（P<0.05）。在治療前，兩組患者的血漿黏度、纖維蛋白原、紅細(xì)胞壓積無(wú)顯著性差異。治療后，兩組患者的血漿黏度、纖維蛋白原、紅細(xì)胞壓積均降低，且治療組的低于對(duì)照組的，差異具有顯著性（P<0.05）。結(jié)論 注射用丹參多酚酸鹽聯(lián)合依達(dá)拉奉治療急性腦梗死與單一使用依達(dá)拉奉相比，近期療效確切同時(shí)改善患者的血液流變學(xué)指標(biāo)，降低患者NIHSS評(píng)分。

Objective This study analyzed the efficacy of Salvianolic Acids for Injection combined with Edaravone in the treatment of acute cerebral infarction, and observed the effect of treatment on hemorheology, so as to judge the clinical value of the combination of two drugs for the treatment of acute cerebral infarction. Methods Eighty patients with cerebral infarction who were treated in our department of neurology from January 2016 to December 2018 were included in the study. Patients were grouped using a random number table method, with 40 patients in the control group. In the control group, edaravone injection was used on the basis of conventional treatment, and the experimental group was supplemented with Salvianolic Acids for Injection. After a course of treatment for 14 days, the effects of the two groups of patients, the effects of blood rheology related indicators before and after treatment, and the improvement of NIHSS scores were compared. Results The NIHSS scores of the two groups were not significantly different before treatment. After two weeks of treatment, the NIHSS score of the experimental group was lower than that of the control group, and the difference was significant (P<0.05). After two weeks of treatment, the total effective rate of the experimental group was higher than that of the control group, and the difference was significant (P<0.05). There were no significant differences in plasma viscosity, fibrinogen, and hematocrit between the two groups before treatment. After two weeks of treatment, the plasma viscosity, fibrinogen, and hematocrit of the experimental group were lower than those of the control group, and the difference was significant (P<0.05). Conclusion Intravenous salvianolate combined with edaravone in the treatment of acute cerebral infarction compared with single use of edaravone, the short-term efficacy of the immediate improvement of the patient's blood rheology indicators, reduce the patient's NIHSS score.

R969.4